All the buying and selling of Portola (PTLA) will not make any sense to us until the firm fulfills its obligations towards what is required by the authorities, by health care and by private third-party payers.  So, in the reporting of its Q2 financial results for the three months ending June 30, 2018, in addition to providing a corporate update, nothing matters really except knowing where the firm has reached in fulfilling the requirement necessary for the full and satisfactory marketing Portola’s approved products.

In this respect, Portola explained that the second quarter of 2018 brought . . .